Association of GSTP1 polymorphism and survival for esophageal cancer
Association of GSTP1 polymorphism and survival for esophageal cancer
复制标题
DOI：
10.1158/1078-0432.ccr-04-2333
复制
发表时间：
2005-07-01
影响因子：
11.5
通讯作者：
Chen, CJ
中科院分区：
文献类型：
--
作者：
Lee, JM;Wu, MT;Chen, CJ
目的：谷胱甘肽S-转移酶（GST）的活性与外源性物质的解毒和细胞活力的维持有关。遗传变异的GST产生不同的酶活性。这种变异的临床意义仍然令人困惑。我们调查GST基因多态性，包括GSTP 1，GSTM 1和GSTT 1是否影响食管癌patients.Experimental Design的生存：从1996年至2002年，233例经病理证实的食管癌患者，从外科，国立台湾大学医院招募。采用PCR或PCR-RFLP方法检测GST基因型，包括GSTT 1、GSTM 1和GSTP 1。采用Kaplan-Meier生存函数法和考克斯比例风险模型估计GSTP 1基因多态性对患者生存的影响。结果：GSTP 1 Ⅱ e/Ⅱ e、Ⅱ e/瓦尔和瓦尔/瓦尔的平均生存时间（月）分别为11、10和7（P < 0.05）。携带GST 1变异瓦尔等位基因的患者越多，生存率越差（校正风险比，1.36; 95%置信区间，1.01-1.84; P趋势= 0.045）。相反，GSTT 1或GSTM 1基因型与生存率无关联。结论：GSTP 1变异等位基因（瓦尔）的存在与食管癌预后不良有关。
Purpose: Activity of glutathione S-transferase (GST) is associated with detoxification of xenobiotics and the maintenance of cell viability Genetically variant GSTs produce different enzymatic activities. The clinical significance of this variation is still puzzling. We investigated whether genetic polymorphisms of GST including GSTP1, GSTM1, and GSTT1 affect survival among esophageal cancer patients.Experimental Design: From 1996 to 2002, 233 patients with pathologically proven esophageal cancer were recruited from the Department of Surgery, National Taiwan University Hospital. GST genotypes, including GSTT1, GSTM1, and GSTP1, were determined by PCR or PCR-RFLP. The influence of the genetic polymorphisms on patient survival was estimated using the method of Kaplan-Meier survival function and Cox proportional hazards models,Results: The mean survival times (months) of the GSTP1 IIe/IIe, IIe/Val, and Val/Val were 11, 10, and 7, respectively (P < 0.05). The more the patients carried GSTP1 variant Val alleles, the poorer the survival rate (adjusted hazard ratio, 1.36; 95% confidence interval, 1.01-1.84; P-trend = 0.045). In contrast, no association of GSTT1 or GSTM1 genotypes with survival rate was noted.Conclusion: The presence of the GSTP1 variant allele (Val) is associated with a poorer prognosis of esophageal cancer.